Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

96 results about "Staphylococcal Enterotoxins" patented technology

Enterotoxin gene cluster (egc) superantigens to treat malignant disease

The use of classical superantigens for treatment of cancer has resulted in a low response rates and serious toxicity in humans which is attributable, in part, to the presence of preformed superantigen specific antibodies in the plasma of treated patients. The present invention addresses this problem by providing a method for treating tumors comprising the administration of one or a plurality of egc (enterotoxin gene cluster) staphylococcal enterotoxins comprising staphylococcal enterotoxins G, I, M, N, O. These superantigens in native unmodified form can be administered intrathecally, intratumorally, intravenously to humans with advanced lung cancer while resolving pleural effusions and prolonging survival to 300% above control patients treated with talc pleurodesis. Intratumoral egc superantigens induces a significant and sustained reduction of the tumor size. In contrast to classic Sags, the egc superantigens induced minimal toxicity, are rarely associated with the presence of preformed antibodies and are used as a plurality with a broad T cell Vβ profile. Useful egc superantigen compositions for parenteral administration native egc enterotoxins, homologues, fragments and fusion proteins of native egc enterotoxins capable of activating a broad spectrum of T cells expressing T cell receptor/α motifs. T cell survival-enhancing cytokines IL-7, Il-15, Il-23 are used. together with parenteral egc SE therapy. Also disclosed is combined therapy that includes parenteral, intratumoral or intrathecal superantigen compositions in combination with (i) intratumoral low, non-toxic doses of one or more chemotherapeutic drugs or (ii) systemic chemotherapy at reduced and non-toxic doses of chemotherapeutic drugs or (iii) radiation therapy or (iv) anti-angiogenic and tyrosine kinase inhibitors.
Owner:TERMAN DAVID S +4

Indirect competitive ELISA (Enzyme Linked Immunosorbent Assay) method based on multi-epitope tandem peptides and used for synchronously detecting staphylococcal enterotoxin A (SEA) and staphylococcal enterotoxin G (SEG)

The invention belongs to the technical field of immunoassay and particularly relates to an indirect competitive ELISA (Enzyme Linked Immunosorbent Assay) method based on multi-epitope tandem peptides and used for synchronously detecting staphylococcal enterotoxin A (SEA) and staphylococcal enterotoxin G (SEG). The method mainly comprises preparation of SEA and SEG multi-epitope tandem peptide peptides (including antigens), preparation of anti-rabbit SEA and SEG antibodies, sample pretreatment and establishment of the indirect competitive ELISA detection method based on multi-epitope tandem peptides. The indirect competitive ELISA method comprises the following steps: (1) enveloping; (2) plate washing; (3) sealing; (4) plate washing; (5) adding standard substances, samples to be detected and specific antibodies in sequence; (6) plate washing; (7) adding ELIAS secondary antibodies; (8) plate washing; (9) developing and ending reaction. The method provided by the invention has the characteristics of high specificity, high sensitivity and good repeatability, is suitable for quick, synchronous and quantificational detection of SEA and SEG in foods such as milk and dairy products.
Owner:ANHUI AGRICULTURAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products